Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | LCAT | P04180 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 2/20 | 0.32 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.31 |
| ▸ | GRM5 | P41594 | 2/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.30 |
| ▸ | PANK3 | Q9H999 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24958923 | 0.78 | GRM5 (0.32) | GRM5GRM1 | |
| SCHEMBL20085557 | 0.77 | LMNA (0.46) | EGLN1ACACBKCNJ1PANK3 | |
| SCHEMBL24958720 | 0.77 | OPRM1 (0.33) | ACACBGRM5GRM1 | |
| SCHEMBL24958910 | 0.73 | JAK2 (0.40) | EGLN1ACACB | |
| SCHEMBL24960023 | 0.72 | MAPT (0.48) | KCNJ1 | |
| SCHEMBL15248218 | 0.69 | CHRNA7 (0.41) | — | |
| SCHEMBL890209 | 0.68 | MAPT (0.47) | EGLN1ACACBPANK3 | |
| SCHEMBL13466387 | 0.68 | KDM4E (0.43) | EGLN1 | |
| SCHEMBL10121068 | 0.68 | ACACB (0.49) | ACACBLCATPANK3 | |
| SCHEMBL15114557 | 0.68 | NOTUM (0.60) | EGLN1KCNJ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021705-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | EGLN1 921/4885ACACB 674/4885LCAT 323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.